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 We report a very rare case of multiple endocrine neoplasia 
type 1 (MEN 1) where a pituitary tumor presenting with 
acromegaly was associated with a growth hormone-releasing 
factor (GRF) producing pancreatic tumor. Twenty-seven 
months after surgery for pituitary adenoma, a 27-year-old 
male visited our hospital complaining of epigastralgia and 
back pain. Radiological examination revealed a 7-cm tumor 
in the pancreatic tail. Endocrinological studies revealed an 
abnormal increase in the level of growth hormone (GH). 
After resection of the pancreatic tumor, the GH level was 
normalized. Immunohistochemical studies confirmed the ex-
istence of GRF in the tumor. A diagnosis of GRF-producing 
pancreatic tumor was established. Nine months after sur-
gery for the pancreatic tumor, the GH level remained nor-
mal and the pituitary gland had decreased in size. We specu-
late that secondary hyperpituitarism was caused by GRF 
produced by the endocrine pancreatic tumor in this case. 
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Introduction 
 Multiple endocrine neoplasia type 1 (MEN 1) is still 
a rare disease, although the number of reported cases 
is on the increase due to advances in hormonal meas-
urement and diagnostic imaging techniques. In 1991, 
Yoshimoto' ) reviewd 45 familial cases (total of 15 
families) and 61 sporadic cases reported in Japan. 
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MEN 1 is characterized by multiple neoplastic lesions 
including hyperplasia, adenoma and cancer arising 
from two or all three of the following endocrine or-
gans: anterior pituitary, parathyroid and pancreatic 
endocrine glands. A gene responsible for MEN I was 
found on the long arm of the 11th chromosome 
(11q13). However, many questions remain unsolved, 
such as why neoplastic lesions occur in the three en-
docrine organs, and why these lesions have various 
histological features ranging from hyperplasia to carci-
noma. We presented a case of MEN 1 associated with 
a growth hormone (GH)-producing pituitary tumor and 
a growth hormone-releasing factor (GRF)-producing 
endocrine pancreatic tumor. The blood GH level was 
normalized and the pituitary gland decreased in size 
following resection of the endocrine pancreatic tumor. 
The interesting course during treatment in this case is 
presented.
Case report 
 Patient: A 27-year-old male. 
 Chief complaint: Epigastralgia and back pain. 
 Past history: The patient, who had developed acromegaly 
and visual disorder, had undergone surgical resection 
of a pituitary tumor (Hardy's operation) at a hospital 
on May 1, 1991. The tumor was pathologically diag-
nosed as a chromophobic adenoma. 
 Family history: Examination revealed no notable ab-
normalities. 
 Present illness: The patient noticed epigastralgia on 
August 19, 1992. The epigastralgia was accompanied 
by severe back pain thefollowing day, which led the 
patient to visit our hospital. He was then hospitalized 
for close examination the same day. 
 Physical findings on admission: Height 178 cm; weight 
75 kg; blood pressure 120/60 mmHg; pulse 62/min and
regular; no anemia or icterus. There were no abnormal 
findings for the neck, chest or abdomen. Acromegaly 
was noted of the face and distal ends of the extremities. 
 Laboratory data on admission: The serum calcium 
(Ca) level was slightly elevated to 10.4 mEq/1, while 
the serum phosphorus (P) level was 3.4 mg/dl and 
within the normal limits. Endocrinological examina-
tion showed an abnormally elevated level of GH, 
slightly increased levels of somatostatin and high sen-
sitive PTH, and decreased levels of prolactin and 
calcitonin (Table 1).
Table 1. Examination results on admission and endocrinological 
findings
 GH 49 ng/ml (<0.42) PTH-M 0.57 ng/ml (<0.8) 
 Prolactin 1 ng/ml (1,5-9,7) H-PTH 630 pg/ml (160-520) 
 Somatostatin 16 pg/ml (1.0-12) ACTH 24 pg/ml (9-52) 
 Insulin 8 uU/ml (<17) TSH 0.6 uU/ml (<1-8) 
 Gastrin 85 pg/ml (<200) T3 1.24 ng/ml (0.85-2) 
 Glucagon 150 pg/ml (40-180) T4 9.8 ug/dl (5.1-13.5) 
 PP 253 pg/ml (114-126) FBS 72 mg/dl (60-110) 
 VIP 5 pg/ml (<10) S-amylase 71 IU/L (45-164) 
 Calitonin 19 pg/ml (36.3-75.7) Ca 10.4 mEq/ml(8.7-10.1) 
 PTH-C 0.4 ng/ml (<0.5) P 3.4 mg/dl (2.4-4.3) 
                                             
( ):within normal limits 
GH,growth hormone; PP, pancreatic polypeptide; VIP,vasoactive intestinal peptide; PTH-C 
and -M, parathyroid hormone-C and -M; H-PTH, high sensitive parathyroid hormone; ACTH, 
adrenocorticotropic hormone; TSH, thyroid stimulating hormone; T3, triiodothyronine; 
T4, thyroxine; FBS, fasting blood sugar
 Abdominal MRI findings: A tumor, 7 cm in diameter, 
possessing a signal intensity lower than that of the 
spleen, was found in the pancreatic tail on T1-
weighted images. The central part of the tumor had 
an even lower signal intensity suggesting necrosis. 
The tumor was slightly enhanced after the administra-
tion of Gd-DTPA contrast medium (Fig.1). 
 Selective angiography of the splenic artery: A lesion 
with a vague tumor stain was found to have a main 
feeder from the dorsal pancreatic artery. 
 Surgical findings: The above findings suggested the 
diagnosis of MEN 1 associated with GH-producing pi-
tuitary adenoma and endocrinepancreatic tumor. The 
patient underwent resection of the pancreatic tumor 
on September 16, 1992. The tumor, covered with a 
well-vascularized capsule, tightly adhered to the 
splenic port, compressing the splenic artery and vein. 
The tail of the pancreas was removed along with the 
spleen. 
 Pathological findings: The encapsulated tumor, 7.5 x 
7.0 x 6.5 cm in size, had a yellow-brown solid cut sur-
face with central necrosis (Fig.2). Microscopically, the 
tumor had a capsule clearly distinguishable from nor-
mal pancreatic tissue (Fig.3 a). The tumor cells showed a
Figure 1. Abdominal MRI: a. A tumor with a 7-cm diameter 
was found in the pancreatic tail on a TI-weighted image. 
The central part of the tumor had a lower signal intensity 
suggesting necrosis. b. The tumor was slightly enhanced after 
the administration of Gd-DTPA.
Figure 2. Macroscopic findings (cut surface): The encapsu-
lated solid tumor measuring 7.5 x 7.0 x 6.5 cm exhibited cen-
tral necrosis.
Figure 3. Histopathological findings a The tumor had a cap 
sule clearly distinguishable from normal pancreatic tissue (HE 
stain, x 40) b Tumor cells showed a funicular or zonate ar 
rangement and a medullary appearance in some parts (HE 
stain, x 100) 
funicular or zonate arrangement and a medullary ap-
pearance in some parts (Fig 3 b) Immunohistochemical 
examination showed that the tumor cells were positive 
for neuron specific enolase (NSE) (Fig 4 a) Chromogranin 
A was also detected in the cytoplasm (Fig 4 b) With 
an immunological staining method (an enzyme antibody 
technique using GRF (1 44) NH2), GRF-positive cells 
were found, although GH staining was negative (Fig 5)
Figure 4 Immunohistochemical findings a The cytoplasm of 
the tumor cells was positive for NSE (x 100) b It was also 
positive for chromogranin A (x 100) 
The tumor cells were negative for Grimehus staining 
Upon electron microscopy, a large number of imma 
ture secretory granules with diameter less than 150 
nm were found in the cell body (Fig 6) 
 Changes in GH during the patient's clinical course 
The GH level was temporarily elevated after resection 
of the pituitary adenoma The value decreased and re 
mained at approximately 10 ng/ml thereafter Before 
surgery for the pancreatic tumor, the GH level in
Figure 5 Immunological staining GRF positive cells were 
found (x 200)
Figure 6 Electron microscopic findings A large number of 
immature secretory granules with a diameter less than 150 
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Figure 7. Changes in GH during the patient's clinical course. 
creased, to 49 ng/ml, again. After the surgery, it 
quickly returned to a value within the normal limits 
(Fig.7). 
 Postoperative course: Nine months after surgery, 
MRI revealed that the pituitary gland had decreased 
in size.
Discussion 
 As for the endocrine pancreatic tumors in MEN 1, sev-
eral histological types have been reported; gastrinomas 
presenting with Zollinger-Ellison syndrome and insulinomas 
causing hypoglycemia are frequently found, while 
vasoactive intestinal peptide (VIP)-producing tumors, 
which cause watery diarrhea, hypokalemia, achlorhydria 
(WDHA) syndrome, and glucagon-producing tumors 
causing glucagonoma syndrome are rather rare. 
Immunohistological studies have also confirmed the 
existence of asymptomatic tumors which produce pan-
creatic polypeptide. Pancreatic tumors produce various 
hormones. 
 In the present case, immunohistochemical examina-
tion confirmed the presence of GRF and the absence 
of GH in the pancreatic tumor. The GH level returned 
to a normal value after surgery. Therefore, it was con-
sidered that GRF was produced in the pancreatic tumor, 
although plasma hormonal concentrations were not 
measured. In 1982, peptides with GRF activity were 
extracted from pancreatic tumors in patients with 
acromegaly to determine the chemical structure 2' 3) . 
The substance possessing GRF activity was found to 
consist of three peptides, GRF (1-44) NH2 GRF (1-40) 
OH and GRF (1-37) OH, with the same structure at 
the N terminus. These peptides are now known as 
pancreatic GRF (pGRF) because they originate from the 
pancreas. Studies at many institutions have confirmed
that pGRF has the same structure as hypothalamus 
GRF. GRF-producing tumors have been attracting the 
attention of investigators as an important disease 
model for the mechanism of acromegaly and pituitary 
pathology in MEN 1. There are 34 reported cases of 
GRF-producing tumors presenting with acromegaly. In 
most of these 34 cases, the pituitary pathology was 
hyperplasia. There are only three cases, including the 
present case, where an adenoma was confirmed. It is 
noteworthy that all three cases were pGRF-producing 
MEN 1. It is still controversial whether excessive se-
cretion of GRF due to GRF-producing tumors can be 
a trigger of hyperplasia in pituitary GH cells. Recent 
genetic investigations suggest that pituitary adenomas 
cannot be generated by GRF stimuli, but they may be 
caused by somatic mutation4). MEN 1 is supposedly 
caused by mutation at the responsible gene at site 
11g135'. 
 Saito et al.'-') reported a case of MEN 1 presenting 
with acromegaly. In their case, the pituitary decreased 
in size and acromegaly improved after resection of a 
GRF-producing pancreatic tumor, although surgery for 
a pituitary tumor was later required due to recurrence 
of symptoms and regrowth of the pituitary. Pituitary 
adenomas are either GH cell adenomas or non-functioning 
adenomas. Acromegaly associated with pancreatic tumor 
is mostly attributable to GH cell hyperplasia caused 
by pGRF. Therefore, it is considered that pituitary 
adenomas arise due to the lack of a cancer-suppressive 
gene at sites 11 q 12-13. In our case, the GH level, which 
decreased after surgery for the pituitary tumor, was 
maintained at a slightly elevated value. Therefore, it 
was suggested that the endocrine tumor was already 
located in the pancreas, and that the adenoma and 
hyperplasia coexisted in the pituitary gland at the time 
of pituitary surgery. After surgery for the pancreatic 
tumor, the GH level normalized and the pituitary gland 
decreased in size. These findings suggest that the pi-
tuitary GH cell hyperplasia returned to normal after 
the removal of pGRF stimuli released from the pancre-
atic tumor. Aida et al. 81 reported a case of MEN 1 pre-
senting with acromegaly where the GH level decreased 
rapidly after surgery for GRF-producing pancreatic 
carcinoid tumor subsequent to resection of a pituitary 
adenoma. In their case, the pituitary function was 
probably elevated by the same mechanism as has been 
speculated in our case. Although adenomas are rarely 
associated with hyperplasia, such condition may occur 
undersecondary hyperpituitarism due to pGRF. 
 As for the generation of pituitary adenoma, the fol-
lowing observations are interesting to note: In one re-
ported case 9' of gangliocytoma in the hypothalamus 
GRF production was accompanied by a GH cell tumor
in the pituitary; GRF-producing pancreatic tumors 
should be classified as endocrine neoplasms according 
to a report10' that pGRF is predominantly found in and 
around islets originating from the ventral primordium 
in the dorsal inferior part of the pancreatic head, and 
is sometimes found in the pancreatic tail; The pancre-
atic endocrine gland has genetic potentials characteris-
tic of the pituitary gland because thyrotropin-releasing 
hormone (TRH), a peptide originally produced in the 
hypothalamus to stimulate the anterior pituitary gland, 
and corticotropin-releasing hormone (CRH) were found 
to exist in the pancreatic endocrine gland"; Ectopic 
GRF-producing tumors are not accompanied by pitui-
tary tumors. These observations may suggest that GRF 
produced in endocrine neoplasms has a close relation-
ship to the generation of pituitary adenomas and the 
proliferation and development of already generated 
adenoma cells. Further studies are necessary to evalu-
ate this hypothesis. 
 Further investigations, including gene analysis of 
the tumor tissue, should be performed in our case to 
establish the participation of pGRF in the generation 
of pituitary adenoma.
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